These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. Abola MV; Prasad V JAMA Intern Med; 2016 Mar; 176(3):389-91. PubMed ID: 26831527 [No Abstract] [Full Text] [Related]
25. Research subjects to be told about conflicts of interest. Maloney DM Hum Res Rep; 2002 Feb; 17(2):3. PubMed ID: 12374175 [No Abstract] [Full Text] [Related]
26. What's wrong with money in science. Stossel T; Shaywitz D Washington Post; 2006 Jul; ():B3. PubMed ID: 16838447 [No Abstract] [Full Text] [Related]
27. Characteristics and conflicts of interest at Food and Drug Administration Gastrointestinal Drug Advisory Committee meetings. Khan R; Elsolh K; Gimpaya N; Scaffidi MA; Bansal R; Grover SC PLoS One; 2021; 16(5):e0252155. PubMed ID: 34038480 [TBL] [Abstract][Full Text] [Related]
28. FDA needs a more "nuanced" approach to advisers' conflicts of interest, researchers say. Dyer O BMJ; 2014 Sep; 349():g5665. PubMed ID: 25227397 [No Abstract] [Full Text] [Related]
29. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007. Wood SF; Perosino KL Public Health Rep; 2008; 123(4):527-30. PubMed ID: 18763416 [No Abstract] [Full Text] [Related]
30. Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees. Graham SS; Card DJ; Ahn S; Kim SY; Kessler MM; Olson MK Ann Intern Med; 2016 Oct; 165(8):606-607. PubMed ID: 27750309 [No Abstract] [Full Text] [Related]
32. Voting behavior during FDA Medical Device Advisory Committee panel meetings. Maisel-Campbell A; Schlessinger DI; Yanes AF; Veledar E; Reynolds KA; Ibrahim SA; Kang BY; Anvery N; Poon E; Alam M PLoS One; 2022; 17(6):e0267134. PubMed ID: 35749461 [TBL] [Abstract][Full Text] [Related]
33. Financial conflicts of interest in biomedical human subject research. Goldstein N J Biolaw Bus; 2006; 9(1):26-37. PubMed ID: 17111525 [TBL] [Abstract][Full Text] [Related]
34. Financial conflicts of interest during meetings of the cardiovascular and renal drugs advisory committee. Bertolino B; Kinder N; Cooper C; Gray H; Arthur W; Ahlander J; Simpson A; Vassar M J Osteopath Med; 2022 Sep; 122(9):445-451. PubMed ID: 35447023 [TBL] [Abstract][Full Text] [Related]
35. Public Speaker Characteristics at Meetings of the Dermatologic and Ophthalmic Drug Advisory Committee and the Ophthalmic Devices Panel. Khattab MH; Weaver M; Cook C; Kinder N; Vassar M Am J Ophthalmol; 2021 Mar; 223():28-32. PubMed ID: 33166500 [TBL] [Abstract][Full Text] [Related]
36. US advisory panellists on drug's safety had ties to manufacturers. Lenzer J; Epstein K BMJ; 2012 Jan; 344():e244. PubMed ID: 22234908 [No Abstract] [Full Text] [Related]
37. Group says FDA, advisory panels show bias toward drug approvals. Vedantam S Washington Post; 2006 Aug; ():A13. PubMed ID: 16941783 [No Abstract] [Full Text] [Related]
38. Institutional review boards should not have primary conflict of interest duty. Maloney DM Hum Res Rep; 2001 Aug; 16(8):1-2. PubMed ID: 11833564 [No Abstract] [Full Text] [Related]
39. Settling for second best? Pitts PJ Nat Biotechnol; 2007 Jul; 25(7):715-6. PubMed ID: 17621285 [No Abstract] [Full Text] [Related]